louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02652689: Diagnosis of Pulmonary Embolism by Doppler Signals
Official title: Transthoracic Parametric Doppler Assessment of Lung Doppler Signals in Acute Pulmonary Embolism
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Pulmonary Embolism
Keywords: pulmonary embolism
pulmonary disease
Lung Doppler signals
Lead sponsor: Echosense Ltd.
Sponsor class: INDUSTRY
First posted: 2016-01-12
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The LDS may contain information of significant diagnostic and physiological value regarding the pulmonary parenchyma and vasculature, as well as the cardio- vascular system in general. In pilot clinical studies of patients with acute decompensated heart failure (ADHF) as well as patients with Pulmonary Hypertension, LDS signals patterns unique to these conditions were identified. We believe that these newly discovered ultrasound signals might provide a non-invasive radiation-free means to diagnose and monitor patients with Pulmonary Embolism.

The purpose of this study is to assess the utility of noninvasive assessment of lung Doppler signals performed via transthoracic parametric Doppler. The objective of the study is to evaluate the lung Doppler signals (LDS) in patients diagnosed with acute PE, in order to determine the potential assessment value of this non-invasive method in this potentially life threatening condition.


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of acute PE on CTA

Exclusion Criteria:

* Pregnant women
* Inability to consent
* Patients with severe chest wall deformity
* Previously diagnosed PE
* Pneumonia
* Pulmonary edema
* Pneumothorax
* Severe COPD (gold class III, IV)
* Hemodynamically unstable patients

Primary outcomes:
measure: Identify lack of Lung Doppler signals in specific lung sections that were diagnosed obstructed by CT
timeFrame: 30min
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam
Study officials:
affiliation: Rambam Health Care Campus
name: Diana Gaitini, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00437489: A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.
Official title: A 16 Week Open-Label Outpatient, Randomized, Parallel Study Assessing The Impact Of Two Different Initial Dose Prescriptions For Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2007-02-21
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is non-inferior compared to the standard weight-based formula.


Eligibility criteria: Inclusion Criteria:

* Diabetes mellitus Type 2
* Currently treated with at least 2 oral anti-diabetic agents

Exclusion Criteria:

* Severe Asthma, severe COPD
* Smoking

Primary outcomes:
measure: Change in HbA1c From Baseline
timeFrame: From baseline to week 16
Secondary outcomes:
measure: Fasting Plasma Glucose, and Overall Absolute, Pre-meal, and Post-meal Blood Glucose Change From Baseline to Week 16 (LOCF)
timeFrame: From baseline to week 16
measure: Number of Subjects Who Experienced Hypoglycemia and Nocturnal Hypoglycemia
timeFrame: week 16
measure: Hypoglycemia Event Rate Per Month
timeFrame: up to week 4 or 16
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Pfizer Investigational Site
city: Karachi
country: Pakistan
facility: Pfizer Investigational Site
state: Sindh
city: Makati
country: Philippines
facility: Pfizer Investigational Site
city: Marikina City
country: Philippines
facility: Pfizer Investigational Site
city: Pasay City
country: Philippines
facility: Pfizer Investigational Site
city: Pasig City
country: Philippines
facility: Pfizer Investigational Site
city: Quezon City
country: Philippines
facility: Pfizer Investigational Site
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00538889: Study Evaluating a Combined Administration of Lecozotan SR and Citalopram in Young Healthy Subjects
Official title: Combined Administration of Lecozotan SR and Citalopram: a Double Blind, Multiple Dose Study in Young Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Adult
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2007-10-03
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the safety and tolerability of lecozotan SR and citalopram when coadministred to healthy subjects.


Eligibility criteria: Inclusion Criteria:

* Signed and dated IRB/IEC-approved informed consent form before any study-specific screening procedures are performed.
* Men or women aged 18 to 50 years, inclusive, at screening.
* Women of nonchildbearing potential, defined as being surgically sterile or postmenopausal for \> 1 year, may be included. For women below 50 years of age, at least two years of retrospective amenorrhea and FSH\>38 and estrogen \<20 are required.
* Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight greater than or equal to 50 kg. BMI is calculated by taking the subject's weight, in kilograms, divided by the square of the subject's average height, in meters, at screening: BMI = weight (kg)/(height \[m\])2

Exclusion Criteria:

* Presence or history of any disorder that may prevent the successful completion of the study.
* Any clinically important deviation from normal limits in physical examination, vital signs, 12-lead ECGs, or clinical laboratory test results.
* Hypersensitivity to citalopram or any of the inactive ingredients in citalopram.

Primary outcomes:
measure: Evaluation of 5-HT toxicity (Hunter serotonin toxicity criteria) and CNS questionnaires.
Secondary outcomes:
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00098189: Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis
Official title: A Follow-Up Study of Patients Previously Treated in a Core Study With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psoriasis
Keywords: Safety, psoriasis, adverse event, SAE, extension
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2004-12-06
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: RETROSPECTIVE

Brief summary: This extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.


Eligibility criteria: Inclusion Criteria:

* Consenting patients who participated in the core clinical trial

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06771089: Effectiveness of a Therapeutic Exercise Protocol Vs a Mobilisation with Movement Protocol in Improving Ankle Dorsiflexion in Amateur Football Players
Official title: A Comparative Study of the Effectiveness of a Therapeutic Exercise Protocol Vs a Mobilisation with Movement Protocol in Improving Ankle Dorsiflexion in Amateur Football Players. Randomised Controlled Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ankle Dorsiflexion
Keywords: Ankle dorsiflexion
Football
Therapeutic exercise
Mobilization with movement
Knee dynamic valgus
Lead sponsor: University of Vigo
Sponsor class: OTHER
Collaborators: name: Iris Machado de Oliveira
name: Aldara Vázquez Méndez
name: Adrian Eiró Fernández
First posted: 2025-01-13
Enrollment: 44
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective: To evaluate and compare the immediate and short-term effectiveness of a therapeutic exercise protocol and a mobilisation with movement protocol, compared with a control group, in improving ankle dorsiflexion in amateur footballers.

Material and methods: A single-blind randomised controlled pilot study was developed. Participants were amateur football players randomized into 3 groups (therapeutic exercise, mobilization with movement and control). The intervention was carried out with 2 weekly sessions for 4 weeks. Assessment tools included the Ankle Lunge Test and the Single Leg Squat.


Eligibility criteria: Inclusion Criteria:

* Football players over 18 years old who train a minimum of 3 days a week.
* Football players with ankle DF less than 9 cm or a difference greater than 1.5 cm between both feet, measured with the Ankle Lunge Test (ALT) using the LegMOtion© device.

Exclusion Criteria:

* Players who, during the ALT, achieve less than 9 cm or a difference greater than 1.5 cm between both feet but reporting limitation due to tension in the gastrocnemius muscle.
* Those with serious traumatic or rheumatological conditions that may interfere with the study.
* Players who have participated in specific programs to improve ankle DF in the last 3 months.
* Players with a history of ankle-foot surgery within the last 6 months.
* Non-registered players training in those clubs.
* Players unable to arrive 20 minutes prior to the beginning of the training session.

Primary outcomes:
measure: Ankle dorsiflexion with Ankle Lunge Test (ALT) using the LegMOtion© device.
timeFrame: 4 weeks
Secondary outcomes:
measure: Dynamic knee valgus with the Single Leg Squat (SLS) test.
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Pontevedra
country: Spain
facility: University of Vigo
Study officials:
References:
Clinical trial NCT05985889: Comparison of Innovative Rehabilitation Treatments and Examination of Their Effectiveness in Stroke Patients
Official title: Comparison of Innovative Rehabilitation Treatments and Examination of Their Effectiveness in Stroke Patients
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Stroke
Keywords: robotic
stroke
rehabilitation
virtual rehabilitation
Lead sponsor: Somogy Megyei Kaposi Mór Teaching Hospital
Sponsor class: OTHER
First posted: 2023-08-14
Enrollment: 75
Sex: ALL
Minimum age (years): 55
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We perform a comparison of several groups. We would like to determine how robotic and virtual therapy is most effective in the treatment of stroke patients. We place great emphasis on walking speed, quality of life, coordination and changes in walking distance.


Eligibility criteria: Inclusion Criteria:

post stroke 6MWT : 120\> minimum after stroke 3 days be a stroke patient first stroke hemiplegia

Exclusion Criteria:

multiple strokes, inability to stand and walk, cognitive function disorder does not reach 50 meters with a minimal walking aid Alcohol Sever heart problem sever demeanor alcoholism drug problems Drug

Primary outcomes:
measure: mRS score
timeFrame: 3 weeks (0-5 score, high score better)
Secondary outcomes:
measure: Barthel index score
timeFrame: 3 weeks
measure: Berg balance score
timeFrame: 3 weeks (0-30, high score better)
measure: 6MWT
timeFrame: 3 weeks
measure: 10m gait speed
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Kaposvár
country: Hungary
facility: Dr. Tollár József
state: Somogy
Study officials:
References:
Clinical trial NCT00173589: Inflammatory and Fibrotic Markers and Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atrial Fibrillation
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-15
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: OTHER

Brief summary: Inflammatory and Fibrotic protein markers in patients with atrial fibrillation


Eligibility criteria: Inclusion Criteria:

* Patients with atrial fibrillation

Exclusion Criteria:

* Patients with atrial fibrillation who are reluctant for the study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Jiunn-Lee Lin
role: STUDY_CHAIR
References:
Clinical trial NCT02028689: Metformin and Furosemide Drug-Drug Interaction Study
Official title: A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate Potential Pharmacokinetic Interaction Between Lesinurad and Metformin and Between Lesinurad and Furosemide in Health Adult Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Ardea Biosciences, Inc.
Sponsor class: INDUSTRY
First posted: 2014-01-07
Enrollment: 23
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study will assess the potential effects of lesinurad on the pharmacokinetics (PK) of metformin and furosemide in healthy, adult male subjects.

Detailed description: Leinurad is a weak in vitro inhibitor of the hepatic transporter OCT1 and the renal transporters OAT1 and OAT3 (OAT1/3). To assess the clinical relevance of these in vitro findings, this clinical study will evaluate the effect of lesinurad on the PK of metformin (OCT1 substrate) and furosemide (OAT1/3 substrate).

Eligibility criteria: Inclusion Criteria:

* Subject has a body weight ≥ 50 kg (110 lbs) and body mass index ≥ 18 and ≤ 30 kg/m2.
* Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment.

Exclusion Criteria:

* Subject has a history or suspicion of kidney stones, prostatic hyperplasia, or urinary stricture.
* Subject has undergone major surgery within 3 months prior to Screening.
* Subject donated blood or experienced significant blood loss (\>450 mL) within 12 weeks prior to Screening or gave a plasma donation within 4 weeks prior to Screening.
* Subject has inadequate venous access or unsuitable veins for repeated venipuncture.

Primary outcomes:
measure: PK profile of metformin and furosemide from plasma
timeFrame: Day 1 and Day 5
measure: PK profile of furosemide from urine
timeFrame: Day 1 and Day 5
Secondary outcomes:
measure: Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters
timeFrame: 5 weeks
Other outcomes:
Locations:
city: Kalamazoo
country: United States
state: Michigan
Study officials:
affiliation: Ardea Biosciences, Inc.
name: S. Bradley
role: STUDY_DIRECTOR
References:
Clinical trial NCT00999089: Arrested Versus Beating Heart Techniques in Coronary Revascularisation
Official title: Arrested Versus Beating Heart Techniques in Coronary Revascularisation: Randomized Clinical Trial in Unselected Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Coronary Artery Bypass Grafting
Keywords: Coronary disease
Coronary artery bypass grafting
Cardiopulmonary bypass
Extracorporeal circulation
Cardioplegia
Off pump
Lead sponsor: Martin-Luther-Universität Halle-Wittenberg
Sponsor class: OTHER
Collaborators: name: Medtronic
First posted: 2009-10-21
Enrollment: 616
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The individual contribution of the specific injuring mechanisms surgical trauma, extracorporeal circulation, and ischemia/reperfusion to clinical outcome in coronary revascularisation remains to be elucidated. The effect of these factors is analyzed in this randomized clinical trial by comparing the 3 surgical approaches: Conventional Coronary Artery Bypass Grafting (CCAB), with extracorporeal circulation and cardioplegic arrest; Off-Pump Coronary Artery Bypass Grafting (OPCAB), avoids extracorporeal circulation and global myocardial ischemia; and Pump-Assisted Coronary Artery Bypass Grafting (PACAB), with an unloaded and beating heart. The hypothesis addressed by the study is that the surgical invasiveness increases in the order: OPCAB, PACAB, CCAB.


Eligibility criteria: Inclusion Criteria:

* patients with double- or triple-vessel coronary artery disease
* patients with left ventricular ejection fraction =\< 40% or \>= 60%
* elective or urgent isolated coronary artery bypass grafting

Exclusion Criteria:

* previous cardiac surgery
* emergency indications

Primary outcomes:
measure: All cause mortality
timeFrame: 1, 6, 12, 24, 48 month
measure: Myocardial infarction
timeFrame: 1, 6, 12, 24, 48 month
measure: Stroke
timeFrame: 1, 6, 12, 24, 48 month
measure: Low-output syndrome
timeFrame: in hospital
measure: duration of ventilation >= 24h
timeFrame: in hospital
measure: New requirement of hemodialysis
timeFrame: in hospital
Secondary outcomes:
measure: Completeness of revascularization
timeFrame: in hospital
measure: Re-revascularization of the target vessel (PCI and/or CABG)
timeFrame: 1, 6, 12, 24, 48 month
measure: Resource use (operative time, duration of stay in the intensive care unit, total hospital stay)
timeFrame: in hospital
Other outcomes:
Locations:
city: Coswig
country: Germany
facility: Heart Center Coswig, Department of Cardiothoracic and Vascular Surgery
city: Halle/Saale
country: Germany
facility: Martin-Luther-University Halle-Wittenberg, Department of Cardiothoracic Surgery
Study officials:
affiliation: Martin-Luther-University Halle-Wittenberg
name: Jochen Boergermann, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Martin-Luther-University Halle-Wittenberg
name: Rolf E Silber, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06217289: A Study on Behavior of Healthcare Professionals Who Handle Oral Solid Drug
Official title: Multicentric Study on Knowledgement and Behaviors of Health Care Professionals Handling Oral Solid Pharmaceutical Forms/Drugs
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Behavior
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2024-01-22
Enrollment: 45
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthcare professionals in charge of drug preparation

Brief summary: A study on behavior of healthcare professionals who handle oral solid drug

Detailed description: A study on behavior of healthcare professionals who handle oral solid drug

Eligibility criteria: Inclusion Criteria:

• Healthcare professionals in charge of drug preparation

Exclusion Criteria:

• There are not exclusion criteria

Primary outcomes:
measure: Observation on behavior of healthcare professional workers during hpreparation of oral solid pharmaceutical drug
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: IRCCS Ospedale San Raffaele
Study officials:
affiliation: IRCCS
name: Maria Fazio
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05373589: Effect of Pressure Support Ventilation During Anesthetic Emergence on Postoperative Atelectasis in Infant
Official title: Effect of Pressure Support Ventilation During Anesthetic Emergence on Postoperative Atelectasis in Infant
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infants Aged 0 Days to 13 Months Scheduled for Elective Surgery
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2022-05-13
Enrollment: 136
Sex: ALL
Minimum age (years): 0
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Atelectasis occurs in patients of all ages who receive mechanical ventilation under general anesthesia, and although fatal cases are rare, it is known as a cause of postoperative hypoxia or fever. In pediatric patients, it has a particularly high incidence of 68-100%, and the incidence is inversely proportional to age. Pediatric patients,compared to adults, have a small capacity for functional residual capacity while a high metabolic demand, making them fundamentally vulnerable to hypoxia. Increased atelectasis during anesthesia causes hypoxia not only during anesthesia but also during recovery after anesthesia. Therefore, it is important to establish and apply a strategy to minimize the occurrence of atelectasis during mechanical ventilation under general anesthesia in pediatric patients. The aim of this study is to investigate whether pressure support ventilation at emergence period could reduce the incidence of postoperative atelectasis in infants undergoing surgery under general anesthesia.


Eligibility criteria: Inclusion Criteria:

1. infant patients aged 0 day to 13 month
2. American Society of Anesthesiologists (ASA) classification 1\~2 who are scheduled for elective surgery under general anesthesia

Exclusion Criteria:

1. patients with symptomatic bronchopulmonary dysplasia
2. patients with uncorrected congenital heart or pulmonary disease
3. Hemodynamically unstable requiring preoperative vasopressor administration
4. fever (\>37.5°) or URI symptoms on the day of surgery

Primary outcomes:
measure: Frequency of atelectasis
timeFrame: Within 5 minutes of arriving at the recovery room
Secondary outcomes:
measure: Frequency of atelectasis
timeFrame: After 30 minutes of stay in the recovery room
measure: scoring of atelectasis
timeFrame: at the time of admission and after 30 minutes of stay in the recovery room
measure: Frequency of desatuation
timeFrame: at the time of admission and after 30 minutes of stay in the recovery room
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University Health System, Severance Hospital
Study officials:
References: